Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
AssigneeInterhealth Nutraceuticals, Inc.
InventorsDebasis Bagchi, Harry G. Preuss, Shil C. Kothari
Life of this patent
Estimating the term…
Abstract
A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.
Claims16
A method for reducing the symptoms of insulin resistance in a person, the method comprising:
- identifying a person suffering from or at risk for suffering from the symptoms;
- and
- administering a composition comprising an effective amount of chromium bound to niacin and three compounds selected from the group consisting of (−) hydroxycitric acid, zinc, trans-resveratrol, gymnemic acid, selenium, an anthocyanidin, allicin and fenugreek that, when administered to the person, reduces the symptoms of insulin resistance.
A method for reducing the symptoms of insulin resistance in a person, the method comprising:
- identifying a person suffering from or at risk for suffering from the symptoms;
- and
- administering a composition comprising an effective amount of chromium bound to niacin and zinc and two compounds selected from the group consisting of (−) hydroxycitric acid, trans-resveratrol gymnemic acid, selenium, an anthocyanidin, allicin and a saponin that, when administered to the person, reduces the symptoms of insulin resistance;
- wherein the amount of zinc in the composition is between:
- about 5 mg and about 50 mg.
A method for reducing the symptoms of insulin resistance in a person, the method comprising:
- identifying a person suffering from or at risk for suffering from the symptoms;
- and
- administering a composition comprising an effective amount of chromium bound to niacin and trans-resveratrol and two compounds selected from the group consisting of (−) hydroxycitric acid, zinc, gymnemic acid, selenium, an anthocyanidin, allicin and a saponin that, when administered to the person, reduces the symptoms of insulin resistance;
- wherein the amount of trans-resveratrol in the composition is between:
- about 5 mg and about 50 mg.
A method for reducing the symptoms of insulin resistance in a person, the method comprising:
- identifying a person suffering from or at risk for suffering from the symptoms;
- and
- administering a composition comprising an effective amount of chromium bound to niacin and selenium and two compounds selected from the group consisting of (−) hydroxycitric acid, trans-resveratrol gymnemic acid, zinc, an anthocyanidin, allicin and a saponin that, when administered to the person, reduces the symptoms of insulin resistance;
- wherein the amount of selenium in the composition is between:
- about 5 mg and about 50 mg.
A method for reducing the symptoms of insulin resistance in a person, the method comprising:
- identifying a person suffering from or at risk for suffering from the symptoms;
- and
- administering a composition comprising an effective amount of chromium bound to niacin, an anthocyanidin and two compounds selected from the group consisting of (−) hydroxycitric acid, trans-resveratrol, gymnemic acid, selenium, zinc, allicin and a saponin that, when administered to the person, reduces the symptoms of insulin resistance;
- wherein the amount of an anthocyanidin in the composition is between:
- about 5 mg and about 50 mg.
A method for reducing the symptoms of insulin resistance in a person, the method comprising:
- identifying a person suffering from or at risk for suffering from the symptoms;
- and
- administering a composition comprising an effective amount of chromium bound to niacin and allicin and two compounds selected from the group consisting of (−) hydroxycitric acid, trans-resveratrol, gymnemic acid, selenium, an anthocyanidin, zinc and a saponin that, when administered to the person, reduces the symptoms of insulin resistance;
- wherein the amount of allicin in the composition is between:
- about 5 mg and about 50 mg.
Dependencies are inferred from the claim text.